Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy.
OBJECTIVE
3-Deoxyglucosone (3-DG), a highly reactive intermediate of the glycation reaction, has been suggested to contribute to the development of diabetes complications. To verify this hypothesis, we assessed the relation between serum 3-DG concentrations and the severity of diabetic microangiopathy in diabetic patients.


METHODS
We conducted a high-performance liquid chromatography assay to determine the serum 3-DG concentrations of 110 diabetic patients with different degrees of severity of diabetic microangiopathy and 57 age-matched control subjects.


RESULTS
The fasting serum 3-DG level in diabetic patients was significantly (P < 0.001) higher than that in control subjects (353 +/- 110 vs. 199 +/- 53 nmol/l). The 3-DG levels were significantly (P < 0.001) elevated even in the diabetic patients showing normoalbuminuria (n = 62, 322 +/- 79 nmol/l) compared with control subjects. The 3-DG levels were further elevated in the patients with microalbuminuria (n = 30, 383 +/- 146 nmol/l) and overt proteinuria (n = 18, 410 +/- 100 nmol/l) (P = 0.027 and P < 0.001 vs. normoalbuminuria group, respectively). This phenomenon was basically reproduced in a category of retinopathy. Furthermore, the diabetic patients with low nerve conduction velocity showed a tendency to display higher 3-DG levels.


CONCLUSIONS
The present results show that the fasting serum 3-DG level is elevated in diabetic patients and that the patients with relatively higher 3-DG levels were prone to suffer from more severe complications, indicating a possible association of 3-DG with diabetic microangiopathy.
Kusunoki
Hitomi
H
Division of Diabetes, Digestive and Kidney Diseases, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
Miyata
Satoshi
S
Ohara
Takeshi
T
Liu
Bing-Fen
BF
Uriuhara
Atsuko
A
Kojima
Hiroshi
H
Suzuki
Kotaro
K
Miyazaki
Hiroyuki
H
Yamashita
Yumiko
Y
Inaba
Kayo
K
Kasuga
Masato
M
D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D003847:Deoxyglucose / Q000031:analogs & derivatives* / Q000097:blood*; D003925:Diabetic Angiopathies / Q000453:epidemiology*; D003928:Diabetic Nephropathies / Q000453:epidemiology; D003930:Diabetic Retinopathy / Q000453:epidemiology; D005215:Fasting; D006442:Glycated Hemoglobin / Q000032:analysis*; D006031:Glycosylation; D006801:Humans; D008875:Middle Aged; D010972:Platelet Activating Factor; D012016:Reference Values
D015415:Biomarkers; D003847:Deoxyglucose; D006442:Glycated Hemoglobin; D010972:Platelet Activating Factor; C016350:3-deoxyglucosone